Aviragen Therapeutics, Inc. 4
4 · Aviragen Therapeutics, Inc. · Filed Apr 5, 2017
Insider Transaction Report
Form 4
COLONNESE MARK P
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2017-04-03$0.66/sh+400,000$262,400→ 775,000 totalExercise: $0.66From: 2017-10-03Exp: 2027-04-03→ Common Stock (400,000 underlying)
Footnotes (1)
- [F1]This stock option vests as follows: 33% of the total stock option vests six (6) months after the grant date, on October 3, 2017 and the remainder of the stock option vests in equal monthly installments beginning November 3, 2017 to April 3, 2018.